[Stocks in Focus] LigaChem Biosciences rises 9% on news of first patient dosing in global clinical trial of targeted ADC
Predicted impact: Low· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)
Same first global trial dosing news; repeat of item 4 with share reaction noted.